The Mucosal Immunity in Human Coronavirus Challenge (MusiCC) project is a global consortium that will lay the crucial groundwork needed to develop the next generation of COVID-19 vaccines that could not only prevent severe disease but also stop SARS-CoV-2 and other coronaviruses from infecting people in the first place, thus blocking the spread of the virus.
Led by Imperial College London and co-funded by the European Union’s Horizon Europe Programme and the Coalition for Epidemic Preparedness Innovations (CEPI), the project will run controlled human infection studies where healthy volunteers will be infected with coronaviruses in order to understand how the immune system can prevent transmission and to test experimental vaccines.
Propose a vaccine candidate
The MusiCC consortium is requesting information from vaccine developers who are currently developing a next-generation SARS-CoV-2 vaccine and are willing to collaborate and provide unlabelled clinical trial grade material (vaccine/placebo and/or device if applicable) for a phase II a/b randomised placebo-controlled vaccine-human challenge trial funded within the project to evaluate immunogenicity and efficacy.
Find out more and download the Expression of Interest form on the MusiCC website.
The deadline to submit your application (in PDF format) is Friday 23 August 2024, 1700 CEST.
If you have any queries, please send them to musicc.consortium@gmail.com